Vitrafy Life Sciences Ltd. · ASX:VFY
Vitrafy Life Sciences — Q1 FY2027 Earnings Presentation
10 slides from Vitrafy Life Sciences's earnings presentation, Oct 28, 2026
Slide 1: Vitrafy Life Sciences Q1 FY2027 Quarterly Update
personal use only Vitrafy Life Sciences Pioneering Technology, Preserving Life. Building the foundational infrastructure for the global biologics economy. Q1 FY2027 Quarterly Update ASX: VFY | October 2026 | vitrafy.com | Strictly Private & Confidential
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer personal use only This presentation is provided by Vitrafy Life Sciences the information contained in this presentation Not financial product advice reasonable, and are not guarantees Limited (ACN 622 720 254) (the Company). or otherwise arising in connection with it.
Slide 3: A Clear Step Up in U.S. Momentum
Q1 FY27 HIGHLIGHTS A Clear Step Up in U.S. Momentum personal use only Blood partnerships executed, CGT entry secured, leading Scientific Advisory Board set-up and FDA listing on track. 3rd ~17% 1st Major U.S. civilian blood partner secured Exposure to U.S. civilian blood collection U.S. cell & gene
Slide 4: U.S. Blood Network
BLOOD U.S. Blood Network personal use only Three civilian partnerships plus the U.S. Army, giving exposure to civilian and sovereign blood networks. Blood Partners Partnership Focus: Red blood cells Partnership Focus: Red blood cells Partnership Focus: Platelets and Plasma Partnership Focus: Platele
Slide 5: Growing Recognition Across the Industry
MARKET DEVELOPMENT Growing Recognition Across the Industry personal use only AABB 2026 put Vitrafy in front of the blood and biotherapies industry leaders, with panel presentations and the introduction of our new Scientific Advisory Board. Scientific Advisory Board Launched at AABB 2026 to advise on
Slide 6: Growing Recognition Across the Industry
MARKET DEVELOPMENT Growing Recognition Across the Industry personal use only Vitrafy also presented its cryopreservation ecosystem and the results of its cryopreserved platelets study were presented by Kristin Reddoch-Cardenas of USAISR. 6
Slide 7: Cell & Gene Therapy and Animal Health
EXPANDING APPLICATIONS Cell & Gene Therapy and Animal Health personal use only One cryopreservation platform, multiple markets. Cell & Gene Therapy Animal Health Charter Medical IMV Technologies Entry into the U.S. cell and gene therapy market Testing and validation continued in Q1 FY2027 Guardion +
Slide 8: Guardion Device Manufacturing
PRODUCT & OPERATIONS Guardion Device Manufacturing personal use only Device fleet scaling across research use, into Medical Device manufacturing Q3 FY2027 following FDA regulatory milestone Guardion devices built per quarter Guardion Manufacturing 9 9 Guardion devices were built during quarter for p
Slide 9: Strong Funding Position Supporting Scale Up
FINANCIAL POSITION Strong Funding Position Supporting Scale Up personal use only Spend shifting from product development to manufacturing, validation and market development. Operating cash costs per quarter (A$m) 6.0 $38.3m $4.9m Cash and term deposits Net operating cash at 30 September 2026 outflow
Slide 10: Building Towards FDA Listing
OUTLOOK Building Towards FDA Listing personal use only Device fleet scaling, regulatory milestone approaching and U.S. team strengthened. H1 FY27 • Guardion U.S. FDA medical device listing • U.S Headquarters secured with CEO relocation • Converting pipeline opportunities across the U.S Blood and CGT
Vitrafy Life Sciences — Q1 FY2027 Earnings Presentation on 6ix